

Inactivation of Factor VIII Coagulant Activity by Two Different Types of Human Antibodies

By Maria S. Giwyt and Leon W. Hoyer

Human antibodies that inactivate factor VIII procoagulant activity (VIII:C) are heterogeneous in their kinetic properties. We report here the properties of four type I and four type II antibodies classified according to Biggs et al. Type I antibodies have second-order inactivation kinetics and completely destroy VIII:C when present in high concentration; type II antibodies have more complex kinetics and do not completely inactivate VIII:C even when tested undiluted. The latter properties correspond to the in vivo finding in some patients that there is detectable VIII:C, even though there is also a significant inhibitor titer. It has been suggested that the antibody-antigen complex in these patients retains some VIII:C activity. This is unlikely, however, since protein-A-Sepharose (PAS) did not adsorb

any VIII:C activity from mixtures of type II antibodies with normal human plasma. An alternate possibility, reduced VIII:C inactivation due to a steric effect of the factor-VIII-related protein (VIII_R, von Willebrand factor), appears to be a more important factor, since three of four type II antibodies had inactivating properties like type I antibodies when they were tested with separated VIII:C instead of plasma. Although the fourth type II antibody did not completely inactivate separated VIII:C, the residual coagulant activity was adsorbed from this mixture by PAS. These data indicate that type II anti-VIII:C react with different antigenic determinants than type I antibodies and that these determinants are partially blocked in the factor VIII complex by VIII_R.

ANTIBODIES TO FACTOR VIII develop in approximately 5%-20% of patients with severe classic hemophilia who require repeated transfusions.¹ They also occur spontaneously as autoantibodies in postpartum women, in patients with autoimmune diseases, and in elderly individuals with no apparent abnormality.² These IgG antibodies inactivate human factor VIII procoagulant activity (VIII:C) and do not react with human factor-VIII-related protein (VIII_R, von Willebrand factor).^{3,4}

The inactivation of VIII:C by these human antibodies is time and temperature dependent.^{5,6} When carefully studied, the inactivation pattern is not uniform, however, and two types of antibodies have been distinguished by kinetic analysis. Type I antibodies, in sufficient quantities, completely inactivate VIII:C and there is a linear relationship when the logarithm of residual VIII:C activity is compared to the antibody concentration.⁷ In contrast, type II antibodies do not completely inactivate VIII:C, even when undiluted. VIII:C inactivation by type II antibodies has a different kinetic pattern as well, with a nonlinear (complex) relationship of residual VIII:C and antibody concentration.⁸ These properties of type II antibodies may be responsible for the observation in some patients that small amounts of VIII:C can be detected even though an inhibitor is present.^{9,10} It has been suggested that the antibody-antigen complexes in these patients retain VIII:C activity⁹ or that there is a spontaneous dissociation of relatively weak immune complexes.¹⁰ To examine these hypotheses, type I and type II human anti-VIII:C have been tested with plasma factor VIII complexes and with separated VIII:C. Both standard inhibition assays and adsorption studies have been carried out.

MATERIALS AND METHODS

Factor VIII Measurements

Factor VIII procoagulant activity (VIII:C) was measured by a one-stage method using factor-VIII-deficient human plasma as substrate.¹¹ Factor VIII procoagulant antigen (VIII:CAg) was measured by an immunoradiometric assay using ¹²⁵I-labeled Fab' prepared from a type I human anti-VIII:C plasma.¹² Factor-VIII-related antigen (VIII_RAg) was determined by an immunoradiometric assay using a rabbit antibody.¹³ The standard (1 U/ml) for all factor VIII measurements was pooled normal human plasma, prepared as previously described.¹⁴

Anti-VIII:C Measurements

Inhibition of VIII:C procoagulant activity was determined by incubating equal volumes of pooled normal human plasma or separated VIII:C with a dilution of antibody plasma for 2 hr at 37°C. The residual VIII:C activity was then measured and in some studies the antibody titer was expressed in Bethesda units.¹⁵ This value was the reciprocal of the antibody plasma dilution that inactivated 50% of the VIII:C activity during the 2-hr incubation. The titer for each antibody plasma was the mean of assays done at five different plasma dilutions.

From the Department of Medicine, University of Connecticut Health Center, Farmington, Conn.

Supported in part by Research Grants HL 16526 and HL 16572 from the National Heart, Lung and Blood Institute and Training Grant AI 01380 from the National Institute of Allergy and Infectious Diseases.

Submitted April 15, 1982; accepted June 14, 1982.

Address reprint requests to Leon W. Hoyer, M.D., Department of Medicine, University of Connecticut Health Center, Farmington, Conn. 06032.

Presented in part at the 23rd Annual Meeting of the American Society of Hematology, San Antonio, Texas, December 2, 1981 (Blood, 58 (Suppl 1): 215a, 1981, abstr).

© 1982 by Grune & Stratton, Inc.
0005-3136/82/030001-00\$01.00/0

Human Anti-VIII:C

Eight antibody plasmas that inactivated VIII:C were studied in detail. One type I antibody was obtained from a patient with no previous hemostatic disorder (Ab1). The other three type I antibody plasmas were obtained from patients with severe chronic hemophilia who had been repeatedly transfused (Ab2-4). All of the four type II antibodies (Ab5-8) occurred as autoantibodies. These plasma samples had been stored at -70°C for 0.5-12 yr before these studies. The inhibitor plasmas were obtained through the helpful cooperation of Drs. E. G. D. Tuddenham, J. Miller, and H. S. Weiss. One plasma (Ab8) was purchased from George King Biomedical, Inc. (Overland Park, Kans.).

The classification of antibodies as type I or type II followed the criteria of Hoyer and coworkers.¹⁴ The relationship of residual VIII:C activity (logarithmic scale) to antibody concentration was determined after a 2 hr incubation with normal plasma at 37°C.

Adsorption of Antibodies and Immune Complexes With Protein-A-Sephadex

Antibody and VIII:C mixtures were incubated with protein-A-Sephadex (PAS) (Pharmacia Fine Chemicals, Piscataway, N.J.) after a 2 hr incubation at 37°C. Excess PAS (0.1 ml of a 10% suspension of PAS beads in saline) was added to 0.1 ml of the mixture and the incubation continued at 37°C for 15 min. The PAS

beads were then removed by centrifugation and the supernatant fluid examined for residual VIII:C. The maximum IgG/PAS ratio in these experiments (10 mg IgG/ml PAS) was well below the capacity of the beads.

In some experiments, human anti-VIII:C antibodies were immobilized by adsorption to PAS before being mixed with VIII:C. After the beads had been incubated with the antibody-containing plasma for 2 hr at room temperature, the beads were washed 1 times with large volumes of barbital-buffered saline (0.015 M NaCl, 0.015 M barbital, 0.010 M sodium barbital, pH 7.5) (BBS). The supernatant fluid was examined in each experiment and it contained less than 2% of the anti-VIII:C activity.

The volume of beads was kept constant in these experiments by employing mixtures of antibody-PAS beads and untreated Sephadex G-25 CL. Untreated normal human plasma or partially purified VIII:C¹⁵ was incubated with an equal volume of the antibody-beads for 1 hr at 37°C and the residual VIII:C was determined in the supernatant fluid after the beads had been removed by centrifugation. PAS beads saturated with normal human plasma IgG served as a control reagent for these studies.

The amount of anti-VIII:C adsorbed to PAS beads was calculated with the assumption that all plasma antibody was bound. This assumption was verified in several studies in which the adsorbed IgG was eluted from washed PAS-antibody beads at pH 2.4. A glycine-NaCl buffer (0.03 M glycine, 0.1 M NaCl, 0.01% sodium azide) was used at a buffer:bead ratio of 5:1 (v/v), the beads removed by centrifugation (7400 g) for 20 min at room temperature, and the supernatant fluid added to 1/40 volume borate buffer (0.1 M boric acid, 0.01 M sodium borate, 0.075 M sodium chloride pH 9.4). After dialysis against 1/100 250 volumes of borate-buffered saline, pH 7.5 (0.016 M boric acid, 0.005 M sodium hydroxide, 0.159 M sodium chloride), the eluate was concentrated to 1 ml by negative pressure ultrafiltration.

The amount of IgG eluted was determined by Laemmli immunoelectrophoresis using rabbit antibodies specific for human gamma




Fig. 1. The inactivation of plasma VIII:C by four type I antibodies. Dilutions of antibody plasma in saline (0.3 ml) and an equal volume of normal plasma were incubated for 3 hr at 37°C prior to the measurement of residual VIII:C activity.




Fig. 2. The inactivation of plasma VIII:C by four type II antibodies. Dilutions of antibody plasma in saline (0.3 ml) and an equal volume of normal plasma were incubated for 2 hr at 37°C prior to the measurement of residual VIII:C activity.

HUMAN ANTI-VIII:C

1105

Table I. Properties of Human Anti-VIII:C

Antibody	Source	1:400 Dilution Units/ml	Class*
1	Autosera pool	800	1
2	Hemophiliac	218	1
3	Hemophiliac	78	1
4	Hemophiliac	14	1
5	Human serum	60	2
6	Autosera pool	58	2
7	Autosera pool	292	2
8	Autosera pool	102	2

* Determined by reaction kinetics and type of VIII:C inhibitor.¹²heavy chains.¹³ The anti-VIII:C titer of the stated IgG was determined in the same way as the plasma samples.¹⁴

RESULTS

The VIII:C inactivating properties of 8 human antibodies were characterized by the method of Biggs and coworkers.¹⁴ Type I antibodies (Ab1-4), at high concentrations, inactivated more than 98% of the VIII:C in a manner consistent with second-order kinetics, resulting in a linear inactivation response (Fig. 1). Undiluted type II antibodies (Ab5-8) did not com-




Fig. 3. VIII:C inactivation by antibody 1. Dilutions of this type I antibody in 0.3 ml saline were tested with 0.3 ml normal human plasma (B) or with separated VIII:C (C). In parallel experiments, 0.3 ml PAS was added to similar mixtures after the initial 2-hr incubation. The residual VIII:C activity was then determined after the PAS beads had been removed by centrifugation from mixtures of Ab1 with normal human plasma (D) or with separated VIII:C (E). Similar patterns were identified using Ab2, 3, and 4.

pletely inactivate plasma VIII:C, and the VIII:C inactivation graph had a curvilinear pattern (Fig. 2). The source, titer, and inactivation patterns of the 8 antibodies are given in Table I.

The basis for nonlinear inactivation by type II antibodies was investigated by incubating plasma-antibody mixtures with protein-A-Sepharose (PAS) to remove most IgG and any immune complexes formed by IgG₁, IgG₂, or IgG₄ antibodies. Preliminary experiments established that all of the anti-VIII:C activity was adsorbed from the inhibitor plasma when a sufficient quantity of PAS was added.

In control studies, the adsorption of type I antibody-plasma mixtures with PAS had minimal effect on VIII:C inactivation (Fig. 3). Similarly, additional VIII:C inactivation was not noted when type II antibody-plasma mixtures were adsorbed with PAS. Typical data are given in Fig. 4 (Ab8) and Fig. 5 (Ab5). Thus, the nonlinear and incomplete VIII:C-inactivating characteristics of type II anti-VIII:C seen when type II antibodies are incubated with plasma cannot be attributed to the formation of immune complexes that retain VIII:C activity.

The potential role of another factor, steric interference by the factor-VIII-related protein (VIIIR, von




Fig. 4. VIII:C inactivation by antibody 8. Dilutions of this type II antibody in 0.3 ml saline were tested with 0.3 ml normal human plasma (B) or with separated VIII:C (C). In parallel experiments, 0.3 ml PAS was added to similar mixtures after the initial 2-hr incubation. The residual VIII:C activity was then determined after the PAS beads had been removed by centrifugation from mixtures of Ab8 with normal human plasma (D) or with separated VIII:C (E). Similar patterns were identified using Ab6 and 7.

1106

SAWYER AND HOYER




Fig. 2. VIII:C inactivation by antibody S: Clusters of type II antibody in 0.3 ml saline were tested with 0.3 ml normal human plasma (0) or with separated VIII:C (1). In parallel experiments, 0.6 ml PAS was added to similar mixtures after the initial 2-hr incubation. The residual VIII:C activity was then determined after the PAS beads had been removed by centrifugation from mixtures of Ab6 with normal human plasma (0) or with separated VIII:C (1).

Willibrand factor), was also considered. In these studies, type I and type II anti-VIII:C were tested with partially purified VIII:C that had VIII:C to VIII:R:Ag ratios greater than 990:1—in contrast to the 1:1 ratio (by definition) in normal plasma.¹³

Type I antibodies had similar properties when tested with separated VIII:C, and the inactivating capacity was only slightly greater than that observed with intact plasma (Fig. 3). Subsequent adsorption of the antibody-VIII:C mixture with PAS had no further effect on the amount of residual VIII:C. Thus, VIII:R did not affect the VIII:C-inactivating properties of the 4 type I antibodies.

In contrast, three of the type II antibodies (Ab6-8) inactivated much more VIII:C when it had been separated from VIII:R (Fig. 4). No further augmentation of antibody potency was observed in these experiments if the antibody-VIII:C mixture was adsorbed with PAS. The other type II antibody, Ab5, retained type II characteristics when tested with separated VIII:C, and its properties were unchanged from those observed with whole plasma (Fig. 5). The adsorption of immune complexes by PAS removed VIII:C activity in this case, however. Thus, VIII:R inhibited VIII:C binding by each of the four type II antibodies. In three cases the antibodies had type I properties when tested with separated VIII:C; in the fourth case (Ab5), the

interaction produced an immune complex that retained VIII:C activity.

VIII:C Inactivation by Immobilized Antibodies

A second group of experiments were carried out with immobilized type I and type II antibodies. The quantity of type I or type II antibody plasma incubated with PAS was chosen so that there would be approximately 100 Bethesda units of anti-VIII:C adsorbed by each milliliter of PAS, and the amount of bound antibody was verified in each case by testing the supernatant fluid. In control experiments, normal human plasma IgG was adsorbed with PAS in the same way.

Immobilized type I anti-VIII:C had the same properties as did the antibody in solution. Both plasma VIII:C and separated VIII:C were inactivated—presumably by removal from solution—and the dose-response pattern was linear (Fig. 6). In contrast, the four type II antibodies adsorbed less VIII:C from plasma when they were bound to PAS (Fig. 7). The immobilized type II anti-VIII:C were potentially reactive, however, for they removed over 98% of the VIII:C activity when incubated with separated VIII:C. This pattern—reduced reactivity with plasma VIII:C and increased reactivity with separated VIII:C—was consistent for each of the four immobilized type II anti-

HUMAN ANTI-VIII:C

1107




Fig. 6. VIII:C inactivation by antibody 1. This figure compares the effect of PEG-immobilized Ab1 incubated with plasma or separated VIII:C for 2 hr at 37°C and Ab1 incubated with an VIII:C source for 2 hr at 37°C prior to the addition of PEG. Similar patterns were obtained with Ab2, 3, and 4.




Fig. 7. VIII:C inactivation by antibody B. This figure compares the effect of PEG-immobilized AbB incubated with plasma or separated VIII:C for 2 hr at 37°C and AbB incubated with an VIII:C source for 2 hr at 37°C prior to the addition of PEG. Similar patterns were obtained with AbB, G, and 7.

beads. As expected, normal human IgG bound to PEG had no effect on either plasma or separated VIII:C, and 95% \pm 7% (1 SD) residual activity was measured in three studies.

Both type I and type II antibodies could be eluted from the PEG with glycine-buffered saline, pH 2.5. Measurement of anti-VIII:C activity recovered in this way verified the calculated amount of antibody that had been immobilized.

The studies with immobilized type II antibodies strongly suggested that VIII:R partially blocks the interaction of type II anti-VIII:C with VIII:C determinants. This conclusion was supported by the demonstration that VIII:R in hemophilic plasma inhibited in a dose-dependent manner the inactivation of separated VIII:C by immobilized type II antibodies (Fig. 8). Hemophilic plasma VIII:R had no effect on the properties of an immobilized type I antibody (Ab1, Fig. 8).

The Effect of Type I and Type II Anti-VIII:C on VIII:CAg and VIII:R:Ag Measurements

Residual VIII:CAg and VIII:R:Ag were measured in each of the studies described above. The residual VIII:CAg levels were similar to most of the VIII:C values, but higher values were noted after some adsorptions. Representative data for a type I antibody (Ab1) and a type II antibody (Ab6) are given in Tables 2 and 3. The immobilized type I and type II antibodies did not remove any VIII:R from plasma (Tables 2 and 3) and the residual VIII:R:Ag content in 10 separate experiments was 97% \pm 4% (1 SD) of that in plasmas incubated with control beads. The separated VIII:C




Fig. 8. The effect of hemophilic plasma on the inactivation of separated VIII:C by PEG-immobilized Ab (type B, ABB type II), and normal IgG. Dilutions of hemophilic plasma made in severe von Willebrand's disease plasma (0.1 ml) were incubated for 2 hr at 37°C with 0.1 ml of immobilized antibody beads and 0.2 ml of separated VIII:C.

Table 2. Protein-A-Sephadex Adsorption of Anti-VIII:C Incubated With Plasma or Separated VIII:C

Antibody	Unbound U/ml	Residual Volume ^a				Antigen Bound Separated U/ml	
		Antigen Plus Plasma					
		VIII:C U/ml	VIII:CAG U/ml	VIII:Ag U/ml	VIII:Ag U/ml		
Ab1	1.5	0.04	0.05	0.48	40.01	0.20	
	0.75	0.21	0.17	0.37	49.01	0.17	
	0.38	0.51	0.30	0.57	56.01	0.24	
Ab5	150	0.03	0.15	0.48	40.01	0.05	
	30	0.13	0.26	0.49	0.22	0.05	
	7.5	0.47	0.24	0.47	0.14	0.17	
Buffer	200	0.48	0.55	0.50	0.44	0.47	

^a Volume of antibody plasma in total volume of 500 μ l. To this was added 200 μ l of either normal plasma or separated VIII:C (1.0 U/ml). The mixture was incubated for 2 hr at 37°C and the IgG adsorbed with 600 μ l Protein A-Sephadex.

1.0 anti-VIII:C source was diluted 1:2 with either plasma or buffer. 0.0 U/ml indicates no loss or inactivation.

had very little VIII:R:Ag (<0.1 U/ml) prior to the adsorption.

DISCUSSION

The inactivation properties of type I and type II human anti-VIII:C have been compared in this study so that the basis for the distinction could be clarified. By studying the ability of protein-A-sephadex to remove residual VIII:C from solutions containing antigen-antibody complexes, we were able to show that four type II antibodies do not form immune complexes that retain VIII:C activity when they are tested with normal human plasma. Similar inactivation data and residual VIII:C values were obtained before and after protein-A-sephadex adsorption of mixtures containing plasma and type II antibodies. If the type II antibodies were immobilized on protein-A-sephadex before being

exposed to plasma, 10%–40% less plasma VIII:C was inactivated (Fig. 7).

In these studies, the less effective VIII:C inactivating properties of type II antibodies appeared to be due to steric inhibition by the VIII:R present in factor VIII complexes. This conclusion was based on the observation that type II antibodies inactivated partially purified VIII:C—free of VIII:R—in the same way as do type I antibodies incubated with plasma. Not all type II antibodies behaved identically, however, for one of them (Ab5) had the same characteristics when tested with separated VIII:C or with plasma (Fig. 5). All VIII:C was removed from the Ab5–VIII:C mixture by protein-A-sephadex, however, while the addition of PAS had no effect on Ab5–plasma mixtures. These results indicate that Ab5 reacts with VIII:C at a site different from that bound by the other type II antibodies. In the case of Ab5, the immune interaction is prevented by VIII:R, but the antigen-antibody complex formed in the absence of VIII:R retains VIII:C activity. Unless the complex is removed from solution, as by adsorption with PAS, Ab5 only inactivates part of the VIII:C activity.

The conclusion that type II antibodies recognize VIII:C antigens separate from the procoagulant site was supported by inhibition experiments in which VIII:R was added back to separate VIII:C (Fig. 8). VIII:C inactivation of PAS–Ab5 was inhibited in a dose-dependent manner by hemophilic plasma.

We conclude that the different kinetic properties of the two kinds of human anti-VIII:C are due to the different kinds of antigenic determinants with which they react.¹⁶ Type I antibodies appear to interact with a group of antigenic determinants near the part of the molecule responsible for procoagulant activity. In contrast, type II antibodies recognize determinants remote from this region, and they are partially inhibited when

Table 3. The Effect of Immobilized Anti-VIII:C on Plasma and Separated VIII:C

Antibody	Volume ^a U/ml	Residual Volume ^b				Antigen Bound Separated U/ml	
		Incubated With Plasma		Incubated With Separated VIII:C			
		VIII:C U/ml	VIII:R:Ag U/ml	VIII:C U/ml	VIII:R:Ag U/ml		
Ab1	10	<0.01	0.11	1.15	10	0.01	
	1	0.14	0.54	1.13	1	0.13	
	0.1	0.87	0.72	1.11	0.1	0.35	
Ab5	150	0.31	0.68	1.20	134	0.04	
	30	0.56	0.56	1.20	30	0.04	
	7.5	0.59	0.54	1.09	10	0.49	
Control (normal plasma)	120	0.90	1.10	1.00	134	0.06	

^a Volume of antibody or antibody plasma adsorbed to 400 μ l protein-A-Sephadex beads (see Methods). These beads were then washed and incubated with 400 μ l ml normal plasma or separated VIII:C (1.0 U/ml) for 2 hr at 37°C.

^b The beads were removed from the mixture by centrifugation and assays done on the supernatant. In this table, 1.0 U/ml indicates no loss or inactivation.

VIII:C is associated with VIII:R in the intact factor VIII complex. This interpretation is consistent with Green's observation that type I antibodies rapidly and completely inactivated the residual VIII:C activity that was left when plasma was incubated with type II antibodies.¹³

It is not certain why type II antibodies partially inhibit VIII:C of normal plasma or why the inactivation-concentration relationship is complex (Fig. 2). This pattern may indicate that there is heterogeneity in the antibody specificity so that some of the antibodies inactivate plasma VIII:C while other antibodies can only react with the separated coagulant protein. Alternatively, and more likely, the heterogeneity in plasma factor VIII may cause some VIII:C to be susceptible to inactivation while other VIII:C is protected by a close interaction with the VIII:R.

Type II antibodies bound to PAS are even less effective in their ability to inactivate plasma VIII:C. In this case, there are potential steric effects produced by both VIII:R and the protein-A- sepharose. As a result, the incomplete VIII:C inactivating properties of type

II antibodies are exaggerated when they are bound to PAS (Fig. 7). Similar observations have been reported for rabbit anti-VIII:C immobilized by coupling to agarose.¹⁴ This steric effect was not detected with type I antibodies (Fig. 5).

Thus, the complex inactivating properties of type II antibodies are due to the antigenic determinants with which they react and the steric interference by the VIII:R protein that partially shields the antigens. In addition, one type II antibody formed an immune complex that retained VIII:C activity. Only one of four type II antibodies had this property, however, and it was demonstrable only when the antibody was added to separated VIII:C. None of the type II antibodies formed VIII:C immune complexes which had residual coagulant activity when they were mixed with unfractionated plasma. For this reason, it is still not certain whether patients with type II antibodies retain some VIII:C activity in immune complexes or if they have, in vivo, a heterogeneous population of VIII:C molecules, some of which retain activity because they are protected by VIII:R.

REFERENCES

1. Shapiro SS, Hultin M: Acquired inhibition in the blood coagulation factors. *Semin Thromb Hemostas* 1:335, 1973
2. Hoyer LW: The factor VIII complex: Structure and function. *Blood* 51:1, 1981
3. Zimmerman TS, Edgington TS: Factor VIII coagulant activity and factor VIII-like antigen: Independent molecular entities. *J Exp Med* 135:1015, 1973
4. Shapiro SS: The immunologic character of acquired inhibition of antihemophilic globulin (factor VIII) and the kinetics of their interaction with factor VIII. *J Clin Invest* 43:147, 1967
5. Biggs R, Austin DEG, Dennis KWE, Rizza CR, Everett R: The mode of action of antibodies which destroy factor VIII. I. Antibodies which have second-order concentration profiles. *Br J Haematol* 23:173, 1972
6. Biggs R, Austin DEG, Dennis KWE, Barber R, Rizza CR: The mode of action of antibodies which destroy factor VIII. II. Antibodies which give complex concentration graphs. *Br J Haematol* 23:177, 1972
7. Biggs R, Dennis KWE, Neufeld HL: A patient with an unusual circulating anticoagulant. *Thromb Diath Haemorrh* 12:1, 1964
8. Bloom AL, Davies AJ, Ross JK: A clinical and laboratory study of a patient with an unusual factor VIII inhibitor. *Thromb Diath Haemorrh* 15:12, 1966
9. Albin JP, Fremond D: Antibodies to factor VIIIa: specificity and kinetics of normal and hetero-antibodies in hemophiliac A. *Blood* 44:373, 1974
10. Breckenridge RT, Ransford OJ: Studies on the nature of the circulating anticoagulant directed against antihemophilic factor VIII. *Br J Haematol* 14:269, 1971
11. Lennarzick J, Hoyer LW: Immunoradiometric measurement of the same VIII procoagulant antigen. *J Clin Invest* 53:1043, 1974
12. Hoyer LW: Immunologic studies of antihemophilic factor (AHF, factor VIII). IV. Radioimmunoassay of AHF antigen. *J Lab Clin Med* 68:822, 1971
13. Hoyer LW, Trabold NC: The effect of thrombin on human factor VIII. *J Lab Clin Med* 57:50, 1951
14. Kasper CK, Alerton LM, Cooley RH, Estes JR, Fratantoni J, Green D, Hampton JW, Hiltzinger MW, Lazarus J, Levine PH, McMullen CW, Pool JG, Shapiro SS, Shulman NR, van Eys J: A more uniform measurement of factor VIII inhibitors. *Thromb Haemost* 14:269, 1971
15. Bjerrum OJ, Ingol A, Lovsetein H, Weitzel B: Quantitation of human IgG by radial immunodiffusion at pH 5 by use of carboxylated antibodies. A routine laboratory method. *Clin Chim Acta* 46:137, 1973
16. Gavril MS, Hoyer LW: Immunologic studies of antihemophilic factor (AHF, VIII:C). VI. Characterization of antigenic determinants using human antibodies. *Clin Immunol Immunopathol* 23:517, 1982
17. Green D: Specificity and inhibition of factor VIII. *Br J Haematol* 15:17, 1968
18. Tran TH, Marler GA, Becker P: Rabbit antibodies against the procoagulant activity (VIII:C) of human factor VIII. *Thromb Haemost* 45:649, 1971